Listen
VELPHORO (sucroferric oxyhydroxide), antihyperphosphatemic
NEPHROLOGY - New medicinal product
Opinions on drugs -
Posted on
Jun 26 2015
Reason for request
Inscription
No clinical benefit demonstrated in the treatment of hyperphosphataemia in patients on dialysis for chronic kidney failure compared with sevelamer carbonate
- VELPHORO has Marketing Authorisation in the control of serum phosphorus levels in chronic kidney failure patients on haemodialysis or peritoneal dialysis
- Its non-inferiority compared with RENVELA (sevelamer carbonate) was demonstrated in terms of control of serum phosphorus levels. Adverse events were observed more commonly with VELPHORO than with sevelamer carbonate, especially those of a gastrointestinal nature, further justifying early treatment discontinuations
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
